Aquestive Therapeutics, Inc. Common Stock

Day range

$3.94 – $4.04

Open

$4.00

Prev close

$4.00

Volume

807.97K

Market cap

$502.05M

Shares out

125.51M

P/E

—

P/S

9.28

P/B

-8.87

P/FCF

—

ROE

138.2%

ROA

-59.2%

Debt/Equity

-0.90

Div yield

0.00%

As of Oct 23, 2026

• Bylaw amendmentOct 19, 2026

  On October 15, 2026, the Board of Directors ... approved and adopted amended and restated bylaws (the "Amended Bylaws"), effective October 15, 2026. The Amended Bylaws supersede the previously existing Amended and Restated Bylaws of the Company.

• Regulatory decisionOct 15, 2026

  Aquestive Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, as complete and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027.

• Licensing agreementOct 14, 2026

  On October 13, 2026, Aquestive Therapeutics, Inc. entered into a license agreement with Eton Pharmaceuticals, Inc. pursuant to which the Company granted Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film.

• Director appointmentSep 29, 2026

  On September 29, 2026, Aquestive Therapeutics, Inc. announced that the Board of Directors of the Company has elected Richard J. Daly as a director of the Company, effective October 14, 2026. Mr. Daly will serve as a Class I director with a term expiring at the Company's 2028 Annual Meeting of Stockholders.

• Investor presentationSep 25, 2026

  Aquestive Therapeutics, Inc. is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. A copy of the Company's investor presentation is attached hereto as Exhibit 99.1.

Days to cover

13.1

Short interest

28.75M

Avg volume

2.2M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
  positiveGlobeNewswire Inc.· Oct 15, 2026
• AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
  negativeGlobeNewswire Inc.· May 2, 2026
• Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
  negativeGlobeNewswire Inc.· Apr 30, 2026
• Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
  negativeGlobeNewswire Inc.· Apr 29, 2026
• Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors
  negativeGlobeNewswire Inc.· Apr 28, 2026